Table 1. Summary of studies eligible for meta analysis, grouped by study methodology.

Author	Year	Region	Study Methodology	N	Intent of Therapy	Other Chemotherapy	KRAS Status	Reported Outcomes
Saridaki 22	2014	Belgium, France, USA	mixed	559	mixed	mixed	unselected	response, PFS, OS
Loupakis 23	2014	California	prospective cohort	113	mixed	irinotecan	wild-type	response, PFS, OS
Garm Spindler 24	2009	Denmark	prospective cohort	71	salvage	irinotecan	unselected	response, PFS, OS
Graziano 25	2008	Italy	prospective cohort	110	salvage	irinotecan	unselected	response, PFS, OS
Inoue 26	2014	Japan	prospective cohort	57	salvage	mixed	wild-type	response, PFS, OS
Sclafani 27	2014	response, PFS, OS	prospective cohort within Phase II trial	105	adjuvant	capecitabine, oxaliplatin	wild-type	response, PFS, OS
Etienne-Grimaldi 28	2012	France	prospective cohort within Phase II trial	52	first-line	irinotecan, folinic acid, UFT	unselected	response, OS
Lurje 29	2008	California	prospective cohort within Phase II trial	130	salvage	none	unselected	response, PFS, OS
Zhang 30	2010	California	prospective cohort within Phase II trial	65	salvage	mixed	unselected	response, TTP, OS
Zhang 31	2011	California	prospective cohort within Phase II trial	111	salvage	none	unselected	response, PFS, OS
Kjersem 32	2012	Norway	prospective cohort within RCT	180	first-line	oxalplatin, folinic acid, UFT	unselected	response, PFS, OS
Kjersem 19	2014	Norway	prospective cohort within RCT	504	first-line	oxalplatin, folinic acid, UFT	unselected	response, PFS, OS
Jonker 2	2015	Canada & Australia	prospective cohort within RCT	138	salvage	none	unselected	response, OS
Hsieh 33	2012	Taiwan	retrospective cohort	118	first-line	oxalplatin, folinic acid, UFT	wild-type	response, PFS, OS
Negri 34	2014	Italy	retrospective cohort	86	mixed	mixed	unselected	response, TTP, OS
Calemma 35	2012	Italy	retrospective cohort	50	mixedC/P	mixed	wild-type	response, PFS, OS
Hu-Lieskovan 36	2011	Europe	retrospective cohort	130	neoadjuvantLA	mixed	unselected	pathologic response
Bibeau 37	2009	France	retrospective cohort	69	salvage	irinotecan	unselected	response, PFS, OS
Dahan 38	2011	France	retrospective cohort	58	salvage	irinotecan	unselected	response, TTP, DSS
Park 39	2012	Korean	retrospective cohort	118	salvage	mixed	unselected	response, PFS, OS
Paez 40	2010	Caucasian	retrospective cohort	104	salvageC/P	mixed	unselected	response, PFS
Sebio 41	2013	Spain	retrospective cohort	100	salvageC/P	mixed	wild-type	response
Geva 18	2015	Europe (multicenter)	retrospective cohort	740	salvage	mixed	wild-type	response, PFS, OS, DCR

N = number participants; UFT = Tegafur/uracil; PFS = progression free survival; OS = overall survival; TTP = time to progression; DSS = disease free survival; LA = patients had locally advanced disease; C/P = patients received either cetuximab and panitumumab